Antiphospholipid syndrome and cancer

Eyal Reinstein*, Yehuda Shoenfeld

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Thrombosis is a frequent complication of cancer that is a substantial cause of morbidity and mortality. The association of antiphospholipid antibodies (aPL) and cancer has been under investigation for several years. Recent findings suggest an increased prevalence of certain cancers in aPL-positive patients; thus, an intensive search for an occult malignancy is prompted in these patients. In addition, several studies reported on elevated levels of aPL in various malignancies; it seems, however, that aPL levels do not reflect their pathogenicity; therefore, their pathological significance in these subset of patients is still elusive. Continuing research on the association between the antiphospholipid syndrome/aPL and malignancies is important, given the potential impact on the understanding and treatment of both antiphospholipid syndrome and cancer.

Original languageEnglish
Pages (from-to)184-187
Number of pages4
JournalClinical Reviews in Allergy and Immunology
Issue number2
StatePublished - Apr 2007


  • Antiphospholipid syndrome
  • Cancer
  • Thrombosis


Dive into the research topics of 'Antiphospholipid syndrome and cancer'. Together they form a unique fingerprint.

Cite this